O	0	10	Evaluation
O	11	13	of
O	14	15	a
O	16	18	30
O	18	19	-
O	19	23	gene
B-intervention	24	34	paclitaxel
I-intervention	34	35	,
I-intervention	36	48	fluorouracil
I-intervention	48	49	,
I-intervention	50	61	doxorubicin
I-intervention	61	62	,
I-intervention	63	66	and
I-intervention	67	83	cyclophosphamide
I-intervention	84	96	chemotherapy
O	97	105	response
O	106	115	predictor
O	116	118	in
O	119	120	a
O	121	132	multicenter
O	133	143	randomized
O	144	149	trial
O	150	152	in
O	153	159	breast
O	160	166	cancer
O	166	167	.

O	168	170	We
O	171	179	examined
O	180	182	in
O	183	184	a
O	185	196	prospective
O	196	197	,
O	198	208	randomized
O	208	209	,
O	210	223	international
O	224	232	clinical
O	233	238	trial
O	239	242	the
O	243	254	performance
O	255	257	of
O	258	259	a
O	260	270	previously
O	271	278	defined
O	279	281	30
O	281	282	-
O	282	286	gene
O	287	296	predictor
O	297	298	(
O	298	302	DLDA
O	302	303	-
O	303	305	30
O	305	306	)
O	307	309	of
O	310	320	pathologic
O	321	329	complete
O	330	338	response
O	339	340	(
O	340	343	pCR
O	343	344	)
O	345	347	to
O	348	360	preoperative
O	361	367	weekly
O	368	378	paclitaxel
O	379	382	and
O	383	395	fluorouracil
O	395	396	,
O	397	408	doxorubicin
O	408	409	,
O	410	413	and
O	414	430	cyclophosphamide
O	431	432	(
O	432	433	T
O	433	434	/
O	434	437	FAC
O	437	438	)
O	439	451	chemotherapy
O	451	452	,
O	453	456	and
O	457	465	assessed
O	466	468	if
O	469	473	DLDA
O	473	474	-
O	474	476	30
O	477	481	also
O	482	490	predicts
O	491	500	increased
O	501	512	sensitivity
O	513	515	to
O	516	519	FAC
O	519	520	-
O	520	524	only
O	525	537	chemotherapy
O	537	538	.

O	539	541	We
O	542	550	compared
O	551	554	the
O	555	558	pCR
O	559	564	rates
O	565	570	after
O	571	572	T
O	572	573	/
O	573	576	FAC
O	577	583	versus
O	584	589	FACx6
O	590	602	preoperative
O	603	615	chemotherapy
O	615	616	.

O	617	619	We
O	620	624	also
O	625	628	did
O	629	631	an
O	632	643	exploratory
O	644	652	analysis
O	653	655	to
O	656	664	identify
O	665	670	novel
O	671	680	candidate
O	681	686	genes
O	687	691	that
O	692	706	differentially
O	707	714	predict
O	715	723	response
O	724	726	in
O	727	730	the
O	731	734	two
O	735	744	treatment
O	745	749	arms
O	749	750	.

B-total-participants	751	754	Two
I-total-participants	755	762	hundred
I-total-participants	763	766	and
I-total-participants	767	774	seventy
I-total-participants	774	775	-
I-total-participants	775	780	three
O	781	789	patients
O	790	794	were
O	795	803	randomly
O	804	812	assigned
O	813	815	to
O	816	823	receive
O	824	830	either
O	831	837	weekly
O	838	848	paclitaxel
O	849	850	×
O	851	853	12
O	854	862	followed
O	863	865	by
O	866	869	FAC
O	870	871	×
O	872	873	4
O	874	875	(
B-intervention	875	876	T
I-intervention	876	877	/
I-intervention	877	880	FAC
O	880	881	,
O	882	883	n
O	884	885	=
B-intervention-participants	886	889	138
O	889	890	)
O	890	891	,
O	892	894	or
B-control	895	898	FAC
O	899	900	×
O	901	902	6
O	903	904	(
O	904	905	n
O	906	907	=
B-control-participants	908	911	135
O	911	912	)
O	913	924	neoadjuvant
O	925	937	chemotherapy
O	937	938	.

O	939	942	All
O	943	951	patients
O	952	961	underwent
O	962	963	a
O	964	976	pretreatment
O	977	981	fine
O	981	982	-
O	982	988	needle
O	989	999	aspiration
O	1000	1006	biopsy
O	1007	1009	of
O	1010	1013	the
O	1014	1019	tumor
O	1020	1023	for
O	1024	1028	gene
O	1029	1039	expression
O	1040	1049	profiling
O	1050	1053	and
O	1054	1063	treatment
O	1064	1072	response
O	1073	1083	prediction
O	1083	1084	.

O	1085	1088	The
B-outcome	1089	1092	pCR
I-outcome	1093	1098	rates
O	1099	1103	were
B-iv-bin-percent	1104	1106	19
I-iv-bin-percent	1106	1107	%
O	1108	1111	and
B-cv-bin-percent	1112	1113	9
I-cv-bin-percent	1113	1114	%
O	1115	1117	in
O	1118	1121	the
O	1122	1123	T
O	1123	1124	/
O	1124	1127	FAC
O	1128	1131	and
O	1132	1135	FAC
O	1136	1140	arms
O	1140	1141	,
O	1142	1154	respectively
O	1155	1156	(
O	1156	1157	P
O	1158	1159	<
O	1160	1161	0
O	1161	1162	.
O	1162	1164	05
O	1164	1165	)
O	1165	1166	.

O	1167	1169	In
O	1170	1173	the
O	1174	1175	T
O	1175	1176	/
O	1176	1179	FAC
O	1180	1183	arm
O	1183	1184	,
O	1185	1188	the
B-outcome	1189	1197	positive
I-outcome	1198	1208	predictive
I-outcome	1209	1214	value
I-outcome	1215	1216	(
I-outcome	1216	1219	PPV
I-outcome	1219	1220	)
O	1221	1223	of
O	1224	1227	the
O	1228	1235	genomic
O	1236	1245	predictor
O	1246	1249	was
B-iv-bin-percent	1250	1252	38
I-iv-bin-percent	1252	1253	%
O	1254	1255	[
O	1255	1257	95
O	1257	1258	%
O	1259	1269	confidence
O	1270	1278	interval
O	1279	1280	(
O	1280	1282	95
O	1282	1283	%
O	1284	1286	CI
O	1286	1287	)
O	1287	1288	,
O	1289	1291	21
O	1291	1292	-
O	1292	1294	56
O	1294	1295	%
O	1295	1296	]
O	1296	1297	,
O	1298	1301	the
B-outcome	1302	1310	negative
I-outcome	1311	1321	predictive
I-outcome	1322	1327	value
O	1328	1331	was
B-iv-bin-percent	1332	1334	88
I-iv-bin-percent	1334	1335	%
O	1336	1337	(
O	1337	1339	95
O	1339	1340	%
O	1341	1343	CI
O	1343	1344	,
O	1345	1347	77
O	1347	1348	-
O	1348	1350	95
O	1350	1351	%
O	1351	1352	)
O	1352	1353	,
O	1354	1357	and
O	1358	1361	the
B-outcome	1362	1366	area
I-outcome	1367	1372	under
I-outcome	1373	1376	the
I-outcome	1377	1385	receiver
I-outcome	1386	1395	operating
I-outcome	1396	1410	characteristic
I-outcome	1411	1416	curve
I-outcome	1417	1418	(
I-outcome	1418	1421	AUC
I-outcome	1421	1422	)
O	1423	1426	was
O	1427	1428	0
O	1428	1429	.
O	1429	1432	711
O	1432	1433	.

O	1434	1436	In
O	1437	1440	the
O	1441	1444	FAC
O	1445	1448	arm
O	1448	1449	,
O	1450	1453	the
B-outcome	1454	1457	PPV
O	1458	1461	was
B-cv-bin-percent	1462	1463	9
I-cv-bin-percent	1463	1464	%
O	1465	1466	(
O	1466	1468	95
O	1468	1469	%
O	1470	1472	CI
O	1472	1473	,
O	1474	1475	1
O	1475	1476	-
O	1476	1478	29
O	1478	1479	%
O	1479	1480	)
O	1481	1484	and
O	1485	1488	the
B-outcome	1489	1492	AUC
O	1493	1496	was
O	1497	1498	0
O	1498	1499	.
O	1499	1502	584
O	1502	1503	.

O	1504	1508	This
O	1509	1517	suggests
O	1518	1522	that
O	1523	1526	the
O	1527	1534	genomic
O	1535	1544	predictor
O	1545	1548	may
O	1549	1553	have
O	1554	1561	regimen
O	1562	1573	specificity
O	1573	1574	.

O	1575	1578	Its
O	1579	1590	performance
O	1591	1594	was
O	1595	1602	similar
O	1603	1605	to
O	1606	1607	a
O	1608	1616	clinical
O	1617	1625	variable
O	1625	1626	-
O	1626	1631	based
O	1632	1641	predictor
O	1642	1650	nomogram
O	1650	1651	.

O	1652	1656	Gene
O	1657	1667	expression
O	1668	1677	profiling
O	1678	1681	for
O	1682	1693	prospective
O	1694	1702	response
O	1703	1713	prediction
O	1714	1717	was
O	1718	1726	feasible
O	1727	1729	in
O	1730	1734	this
O	1735	1748	international
O	1749	1754	trial
O	1754	1755	.

O	1756	1759	The
O	1760	1762	30
O	1762	1763	-
O	1763	1767	gene
O	1768	1777	predictor
O	1778	1781	can
O	1782	1790	identify
O	1791	1799	patients
O	1800	1804	with
O	1805	1812	greater
O	1813	1817	than
O	1818	1825	average
O	1826	1837	sensitivity
O	1838	1840	to
O	1841	1842	T
O	1842	1843	/
O	1843	1846	FAC
O	1847	1859	chemotherapy
O	1859	1860	.

O	1861	1868	However
O	1868	1869	,
O	1870	1872	it
O	1873	1881	captured
O	1882	1891	molecular
O	1892	1903	equivalents
O	1904	1906	of
O	1907	1915	clinical
O	1916	1925	phenotype
O	1925	1926	.

O	1927	1931	Next
O	1931	1932	-
O	1932	1942	generation
O	1943	1953	predictive
O	1954	1961	markers
O	1962	1966	will
O	1967	1971	need
O	1972	1974	to
O	1975	1977	be
O	1978	1987	developed
O	1988	1998	separately
O	1999	2002	for
O	2003	2012	different
O	2013	2022	molecular
O	2023	2030	subsets
O	2031	2033	of
O	2034	2040	breast
O	2041	2048	cancers
O	2048	2049	.
